Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Melphalan Flufenamide Noninferior to Pomalidomide in Relapsed/Refractory Myeloma

May 26th 2021

Melphalan flufenamide has been shown to be noninferior to pomalidomide in the treatment of patients with relapsed/refractory multiple myeloma.

Novel Therapies Under Study for Triple-Class Refractory Multiple Myeloma

May 25th 2021

Novel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.

Addressing Unmet Needs for Triple-Class Refractory Multiple Myeloma

May 25th 2021

Current unmet needs surrounding the management of patients with triple-class refractory multiple myeloma with newer novel therapies.

Individualizing Therapy for Triple-Class Refractory Myeloma

May 25th 2021

Guidance regarding proper treatment selection and sequencing of therapies for triple-class refractory multiple myeloma.

Dr. Ghosh on the Impact of Ide-Cel in Relapsed/Refractory Multiple Myeloma

May 25th 2021

Monalisa Ghosh, MD, discusses the impact of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Dr. Diamond on the Need to Integrate MRD Testing Into Clinical Trials in Multiple Myeloma

May 21st 2021

Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.

Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple Myeloma

May 20th 2021

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Dr. Pianko on the Role of Daratumumab in Frontline Myeloma

May 18th 2021

Matthew James Pianko, MD, discusses the role of daratumumab in the frontline treatment of multiple myeloma.

Modernized Clinical Trials Include Diverse Representation, Decentralization, and Real-World Data in Post–COVID-19 Era

May 18th 2021

Silver linings of the COVID-19 pandemic have opened the door for new opportunities for decentralized clinical trials and real-world data in a post–COVID-19 world.

Single-Agent Belantamab Mafodotin for Triple-Class Refractory Multiple Myeloma

May 18th 2021

An overview of the DREAMM-2 study of belantamab mafodotin for triple-class refractory patients with multiple myeloma, with special considerations for managing treatment-related corneal events.

Melflufen and Dexamethasone for Triple-Class Refractory Multiple Myeloma

May 18th 2021

The rationale for adding melflufen to dexamethasone as treatment for patients with triple-class refractory multiple myeloma.

CAR T-Cell Therapy UCARTCS1A Shows Early Activity in Relapsed/Refractory Myeloma

May 14th 2021

UCARTCS1A demonstrated early antitumor activity in heavily pretreated patients with relapsed/refractory multiple myeloma in whom previous CAR T-cell therapy and/or transplant had failed, according to preliminary data from the phase 1 MELANI-01 trial.

Isatuximab, Melflufen Combos Seek to Move the Needle in Relapsed/Refractory Myeloma

May 14th 2021

Novel combinations are paramount for patients with relapsed/refractory multiple myeloma who are in second relapse or beyond; some isatuximab-irfc–containing regimens have the potential to move to the frontline setting and combining melphalan flufenamide with proteasome inhibitors and anti-CD38 monoclonal antibodies is an active area of interest.

Dr. Landgren on the Clinical Impact of KRd-D in Multiple Myeloma

May 13th 2021

Ola Landgren, MD, PhD, discusses the clinical impact of the 4-drug combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in patients with multiple myeloma.

Dr. Marron on the Population Included in a Phase 1 Study of PGV-001 Neoantigen Cancer Vaccine

May 13th 2021

Thomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.

Ide-Cel Proves Highly Effective in Relapsed/Refractory Myeloma

May 13th 2021

Nikhil C. Munshi, MD, discusses how idecabtagene vicleucel has potentially marked the beginning of a new chapter for cellular therapy in multiple myeloma.

Whole-Genome Sequencing in Smoldering Myeloma and MGUS Could Predict Outcomes

May 12th 2021

Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their research with whole-genome sequencing in patients with precursor conditions, and spotlight next steps for research.

An Expanding Armamentarium Calls for Tailored Therapy in Relapsed/Refractory Myeloma

May 12th 2021

The treatment paradigm for relapsed/refractory multiple myeloma has expanded rapidly with the recent integration of selinexor and BCMA-directed therapies, such as belantamab mafodotin-blmf and idecabtagene vicleucel.

Weekly Carfilzomib Quadruplet Induces High Rates of MRD Negativity, PFS in Newly Diagnosed Myeloma

May 11th 2021

The quadruplet combination comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab was linked with high rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma.

Dr. Kröger on Toxicities Associated With Allogeneic Stem Cell Transplant in Myeloma

May 11th 2021

Nicolaus Kröger, MD, discusses toxicities associated with allogeneic stem cell transplant in patients with multiple myeloma.